Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, placebo-controlled Phase IIa study of C21 on idiopathic pulmonary fibrosis (IPF) patients

Trial Profile

A double-blind, placebo-controlled Phase IIa study of C21 on idiopathic pulmonary fibrosis (IPF) patients

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2018

At a glance

  • Drugs C-21 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jul 2018 New trial record
    • 03 Jul 2018 According to a Vicore Pharma media release, the company has received approval for this trial to be initiated in 2020.
    • 18 Apr 2018 According to a Vicore Pharma media release, this trial will be conducted with clinical research partners at different hospitals and with PAREXEL. Dr Joanne Porter at the University College of London (UCL) is the principle investigator for the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top